Immunological and non-immunological features specific to Long-COVID: multiple overlapping aetiologies and potential biomarkers

Long-COVID (LC) is a serious clinical condition characterised by debilitating fatigue together with a wide array of symptoms that significantly reduce the quality of life of patients. Currently no holistic or even symptom specific treatment options are available, likely due to both a lack of insight into the disease processes that drive LC symptoms and an extreme heterogeneity in patients profiles. We characterised patients and post infection controls, with respect to their immunological profiles with a non-exhaustive panel of biomarkers rationalised based on their potential role in driving symptoms. We observed that the patients symptoms could be grouped into 4 clusters suggesting possible stratification. Systemic inflammation persisted and did not normalize over time in LC. This was not related to persistent SARS-CoV-2 infection, as the presence of circulating N-protein was detected similarly in both patients and controls. No obvious deviation in B-cells and monocytes profiles were observed with minor changes for NK-cells (CD62L+/CD16+/HLA-DR+). Major changes affected CD4+T-cells (and to a lesser extent CD8+T-cells) with respect to exhaustion (PD1+/LAG3+/CD44+), regulation (Treg) and differentiation (naive/memory-CD62L+). Several candidate biomarkers (cytokines, microRNAs, phosphate metabolism) were present more frequently in LC at high levels and provided information on underlying disease processes. While frequencies of candidate autoantibody+ participants were not different, levels of some antibodies were higher in LC. Yet none of these candidates stood out as a universal biomarker for LC, with the exception of CRP (73% cases), and loss of Treg (50%). However, we confirmed that several overlapping underlying aetiologies may be involved in this complex disease. Specific groups of biomarkers also associated with the 4 cluster of patients. Although to be taken with caution due to small numbers, 3 biomarkers discriminated controls from patients (Treg/CD4+PD1+/CD4+CD161+), others were associated with symptoms recovery (low IL10/IL12/IL4 and high miR766) or deterioration (high CD4+CD38+/ CD8+naiveCD62L+/low IL2) over 12 months. This study provides rational for developing targeted therapeutic strategies as well as biomarkers to stratify LC patients most likely to respond.